Antibody biomarkers in CNS demyelinating diseases – a long and winding road
- 24 May 2015
- journal article
- review article
- Published by Wiley in European Journal of Neurology
- Vol. 22 (8) , 1162-1168
Abstract
Over several decades, studies sought potential markers to diagnose and to predict the clinical course of central nervous system (CNS) demyelinating disorders, especially in multiple sclerosis, acute disseminated encephalomyelitis and neuromyelitis optica spectrum disorders. Reliable biomarkers would ensure correct diagnoses, determine future disease evolvements, stratify patients for appropriate treatments and monitor disease activity and treatment effects - in summary, meet the longing for personalized medicine in these diseases. Out of a plethora of potential biomarker candidates antibodies have turned (again) into the scientific focus, due to pivotal immunological and neuropathological findings in the past 20 years. A major breakthrough and stimulus for further research was the identification of anti-aquaporin-4 antibodies in neuromyelitis optica. Various other myelin and non-myelin antigens were investigated in detail for diagnostic and prognostic purposes, such as antibodies to myelin oligodendrocyte glycoprotein or to the potassium channel KIR4.1. Further, the use of biopharmaceutical treatments in multiple sclerosis led to intense research activities to identify anti-treatment neutralizing antibodies and their clinical consequences. This review briefly summarizes the current knowledge on antibodies in the diagnosis, prognosis, disease and treatment monitoring of CNS demyelinating disorders.Keywords
Funding Information
- EuroImmun
This publication has 64 references indexed in Scilit:
- Neurofilaments as biomarkers in multiple sclerosisMultiple Sclerosis Journal, 2012
- Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disordersJournal of Neuroinflammation, 2011
- Age-Dependent B Cell Autoimmunity to a Myelin Surface Antigen in Pediatric Multiple SclerosisThe Journal of Immunology, 2009
- Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosisProceedings of the National Academy of Sciences, 2008
- Lack of Association between Antimyelin Antibodies and Progression to Multiple SclerosisNew England Journal of Medicine, 2007
- Antimyelin Antibodies with No Progression to Multiple SclerosisNew England Journal of Medicine, 2007
- Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured proteinNature Medicine, 2007
- Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosisProceedings of the National Academy of Sciences, 2006
- Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating eventJournal of Neurology, Neurosurgery & Psychiatry, 2006
- Clinical, radiological, immunological and pathological findings in inflammatory CNS demyelination-possible markers for an antibody-mediated processMultiple Sclerosis Journal, 2001